Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038390 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNA4AKR1C3CHRNB4CHRNA3 | |
| SCHEMBL6624732 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNA4AKR1C3CHRNB4CHRNA3 | |
| SCHEMBL5037260 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNA4AKR1C3 | |
| SCHEMBL2723382 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNA4AKR1C3 | |
| SCHEMBL5367897 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNA4AKR1C3 | |
| SCHEMBL16872560 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNA4AKR1C3 | |
| SCHEMBL5034132 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNA4AKR1C3 | |
| SCHEMBL11963169 | 0.82 | CCR2 (0.44) | CHRNB2CHRNA4AKR1C3 | |
| SCHEMBL6624576 | 0.81 | CHRNA7 (0.49) | CHRNB2CHRNA4AKR1C3 | |
| SCHEMBL20136777 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4AKR1C3CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359152-B1 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LAB (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | CHRNB2 29/4885CHRNA4 14/4885AKR1C3 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.